Skip to Main Content

Key Action Statement Profile: KAS 4C

Aggregate evidence quality Grade B 
Benefits Identify children who may have AOM caused by pathogens resistant to previous antibiotics. 
Risks, harms, cost Cost. Time for patient and clinician to make change. Potential need for parenteral medication. 
Benefit-harm assessment Preponderance of benefit. 
Value judgments None. 
Intentional vagueness “Reassess” is not defined. The clinician may determine the method of assessment. 
Role of patient preferences Limited. 
Exclusions Appearance of TM improved. 
Strength Recommendation 
Aggregate evidence quality Grade B 
Benefits Identify children who may have AOM caused by pathogens resistant to previous antibiotics. 
Risks, harms, cost Cost. Time for patient and clinician to make change. Potential need for parenteral medication. 
Benefit-harm assessment Preponderance of benefit. 
Value judgments None. 
Intentional vagueness “Reassess” is not defined. The clinician may determine the method of assessment. 
Role of patient preferences Limited. 
Exclusions Appearance of TM improved. 
Strength Recommendation 
Close Modal

or Create an Account

Close Modal
Close Modal